NASDAQ:CADL Candel Therapeutics (CADL) Stock Price, News & Analysis $10.84 -0.51 (-4.45%) Closing price 09/18/2026 03:59 PM EasternExtended Trading$10.84 0.00 (0.00%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Candel Therapeutics Stock (NASDAQ:CADL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Candel Therapeutics alerts:Sign Up Key Stats Today's Range$10.78▼$11.3850-Day Range$9.40▼$13.7552-Week Range$4.35▼$14.00Volume3.01 million shsAverage Volume1.10 million shsMarket Capitalization$829.09 millionP/E RatioN/ADividend YieldN/APrice Target$19.29Consensus RatingModerate Buy Company Overview Candel Therapeutics, Inc. is a clinical-stage biotechnology company developing multimodal biological immunotherapies designed to stimulate the immune system to recognize and attack cancer. The company focuses on engineered viruses administered directly into tumors, with the goal of creating a localized immune response that may also affect cancer cells elsewhere in the body. Candel’s pipeline includes CAN-2409, an investigational, replication-defective adenovirus-based immunotherapy being studied in cancers including localized prostate cancer and non-small cell lung cancer. The company is also developing CAN-3110, an investigational oncolytic herpes simplex virus intended for the treatment of recurrent glioblastoma. These programs are supported by Candel’s enLIGHTEN discovery platform, which is designed to generate and evaluate novel viral immunotherapies. Founded in 2015 and headquartered in Needham, Massachusetts, Candel conducts its research and clinical development activities primarily in the United States. The company’s products remain investigational and are not approved for commercial use. Candel is led by President and Chief Executive Officer Paul Peter Tak, M.D., Ph.D.AI Generated. May Contain Errors. Read More Candel Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreCADL MarketRank™: Candel Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 308th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingCandel Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on no strong buy ratings, 8 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialCandel Therapeutics has a consensus price target of $19.29, representing about 78.0% upside from its current price of $10.84.Amount of Analyst CoverageCandel Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Candel Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Candel Therapeutics are expected to grow in the coming year, from ($1.29) to ($1.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Candel Therapeutics is -7.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Candel Therapeutics is -7.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCandel Therapeutics has a P/B Ratio of 11.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Candel Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.70% of the float of Candel Therapeutics has been sold short.Short Interest Ratio / Days to CoverCandel Therapeutics has a short interest ratio ("days to cover") of 9.19.Change versus previous monthShort interest in Candel Therapeutics has recently decreased by 1.59%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCandel Therapeutics does not currently pay a dividend.Dividend GrowthCandel Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News SentimentN/A News SentimentCandel Therapeutics has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Candel Therapeutics this week, compared to 4 articles on an average week.Search Interest5 people have searched for CADL on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Candel Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Candel Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $390,017.00 in company stock.Percentage Held by Insiders14.30% of the stock of Candel Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions13.93% of the stock of Candel Therapeutics is held by institutions.Read more about Candel Therapeutics' insider trading history. Receive CADL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Candel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CADL Stock News HeadlinesCandel Therapeutics, Inc. (NASDAQ:CADL) Receives $19.29 Consensus Target Price from AnalystsSeptember 14, 2026 | americanbankingnews.comCandel Therapeutics Adds Regulatory Executive Martine Zimmermann To Board As BLA Filing NearsSeptember 11, 2026 | rttnews.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.September 19 at 1:00 AM | Chaikin Analytics (Ad)Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of DirectorsSeptember 10, 2026 | globenewswire.comCandel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 1, 2026 | globenewswire.comShow Me The Money: CADL Delivers 190%+ Gain In Less Than Six Months As BLA Filing NearsAugust 28, 2026 | rttnews.comCandel Therapeutics to Present at September Investor ConferencesAugust 26, 2026 | globenewswire.comCandel Therapeutics (CADL) Is Up 5.4% After Steep Q2 Loss Widening Has The Bull Case Changed?August 21, 2026 | finance.yahoo.comSee More Headlines CADL Stock Analysis - Frequently Asked Questions How have CADL shares performed this year? Candel Therapeutics' stock was trading at $5.65 at the beginning of the year. Since then, CADL stock has increased by 91.8% and is now trading at $10.8350. How were Candel Therapeutics' earnings last quarter? Candel Therapeutics, Inc. (NASDAQ:CADL) issued its earnings results on Thursday, August, 13th. The company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by $0.28. When did Candel Therapeutics IPO? Candel Therapeutics (CADL) raised $72 million in an initial public offering (IPO) on Tuesday, July 27th 2021. The company issued 9,000,000 shares at a price of $8.00 per share. Jefferies, Credit Suisse, BMO Capital Markets and UBS Investment Bank acted as the underwriters for the IPO. Who are Candel Therapeutics' major shareholders? Top institutional investors of Candel Therapeutics include BlackRock Inc. (6.78%), Bank of America Corp DE (0.36%), Wellington Management Group LLP (0.27%) and Bank of New York Mellon Corp (0.26%). Insiders that own company stock include Paul B Manning, Estuardo Aguilar-Cordova, Paul Peter Tak, Francesca Barone, Seshu Tyagarajan, William Garrett Nichols and Charles Schoch. View institutional ownership trends. How do I buy shares of Candel Therapeutics? Shares of CADL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Candel Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Candel Therapeutics investors own include Advanced Micro Devices (AMD), Netflix (NFLX), NVIDIA (NVDA), Tesla (TSLA), Alphabet (GOOG), Meta Platforms (META) and Visa (V). Company Calendar Last Earnings8/13/2026Today9/19/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 CADL's financial health is in the Green zone, according to TradeSmith. CADL has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CADL CIK1841387 Webwww.candeltx.com Phone617-916-5445FaxN/AEmployees55Year Founded1999Price Target and Rating Average Price Target for Candel Therapeutics$19.29 High Price Target$25.00 Low Price Target$12.00 Potential Upside/Downside+78.0%Consensus RatingModerate Buy Rating Score (0-4)2.64 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($1.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$38.18 million Net MarginsN/A Pretax MarginN/A Return on Equity-76.98% Return on Assets-48.50% Debt Debt-to-Equity Ratio0.38 Current Ratio16.09 Quick Ratio16.09 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.95 per share Price / Book11.41Miscellaneous Outstanding Shares76,520,000Free Float65,577,000Market Cap$829.09 million OptionableOptionable Beta-0.48 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:CADL) was last updated on 9/19/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Candel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Candel Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
